NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

抗病毒藥物市場規模調查:COVID-19按藥物,分佈的累積影響(∼2025年)

Antiviral Therapeutics Market Research Report by Drug, by Therapy, by Distribution, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版商 360iResearch LLP 商品編碼 989540
出版日期 內容資訊 英文 199 Pages
商品交期: 最快1-2個工作天內
價格
抗病毒藥物市場規模調查:COVID-19按藥物,分佈的累積影響(∼2025年) Antiviral Therapeutics Market Research Report by Drug, by Therapy, by Distribution, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
出版日期: 2021年06月01日內容資訊: 英文 199 Pages
簡介

全球抗病毒藥物市場預計將從2020年的56,891.37百萬美元增長到2025年底的81,384.43百萬美元。

市場細分和覆蓋率

這項研究對全球抗病毒藥物市場進行了分類,預測了收入,並分析了以下每個子市場的趨勢:

    通過藥物,對HIV抗病毒藥,肝炎抗病毒藥,皰疹抗病毒藥和流感抗病毒藥進行了抗病毒藥物市場調查。
  • 通過分佈,對醫院藥房,獨立藥房和藥房以及在線藥房的抗病毒藥物市場進行了調查。
  • 按地區,在美洲,亞太地區,歐洲和中東/非洲對抗病毒藥物市場進行了調查。在美洲,曾在阿根廷,巴西,加拿大,墨西哥和美國對它進行過調查。在亞太地區,在澳大利亞,中國,印度,印度尼西亞,日本,馬來西亞,菲律賓,韓國和泰國進行了調查。歐洲,中東和非洲在法國,德國,意大利,荷蘭,卡塔爾,俄羅斯,沙特阿拉伯,南非,西班牙,阿拉伯聯合酋長國和整個英國進行了調查。

COVID-19的累積影響

預計COVID-19將在預測期內對行業增長產生長期影響,因為這是無與倫比的全球公共衛生突發事件,幾乎影響了每個行業。我們正在進行的研究擴大了研究框架,以確保它包括潛在的COVID-19問題和潛在的未來路徑。該研究提供了對COVID-19的見解,並考慮了消費者行為和需求,購買模式,供應鏈改路,當前市場勢力動態以及政府的主要干預措施的變化。更新後的調查提供了見解,分析,估計和預測,其中考慮了COVID-19對市場的影響。

報告提供了有關以下準則的見解:

  • 1. 市場滲透率:主要參與者提供的全面市場信息
  • 2. 市場開發:有利可圖的新興市場的詳細信息和市場分析
  • 3. 市場多元化:有關新產品發佈,欠發達地區,最新發展和投資的更多信息
  • 4. 競爭評估和情報:全面評估領先公司的市場份額,戰略,產品和製造能力
  • 5. 產品開發和創新:對未來技術,研發活動和新產品開發的見解

報告回答以下問題:

  • 1. 全球抗病毒藥物市場的規模和預測是什麼?
  • 2. 在預測期內,將影響全球抗病毒藥物市場的COVID-19的抑製劑和作用是什麼?
  • 3. 在全球抗病毒藥物市場的預測期內,您將投資哪些產品/細分/應用/領域?
  • 4. 全球抗病毒藥物市場的競爭性戰略機會窗口是什麼?
  • 5. 全球抗病毒藥物市場趨勢技術趨勢和監管框架是什麼?
  • 6. 被認為適合進入全球抗病毒藥物市場的方式和戰略舉措是什麼?

本報告調查了抗病毒治療藥物市場,分析了市場概況,市場增長和抑制因素,市場規模趨勢以及按藥物,分佈和地區,競爭狀況以及主要公司做出的預測,並提供了諸如簡介等全面信息。和市場機會。

目錄

第1章前言

  • 調查目的
  • 市場細分和覆蓋範圍
  • 調查目標年度
  • 貨幣和價格
  • 語言
  • 限制
  • 利益相關者

第2章調查方法

  • 調查過程
    • 定義:調查目的
    • 決策:調查設計
    • 準備:測量設備
    • 集合:數據源
    • 分析:數據解釋
    • 公式:數據驗證
    • 發佈:調查報告
    • 重複:報告更新
  • 進行調查
    • 開始:調查過程
    • 計劃:創建調查計劃
    • 執行:進行調查
    • 驗證:發現和分析
    • 出版物:調查報告
  • 調查結果

第3章執行摘要

  • 簡介
  • 市場前景
  • 製藥前景
  • 分銷前景
  • 區域展望
  • 競爭對手展望

第4章市場概述

  • 簡介
  • COVID-19的累積效果

第5章市場洞察

  • 市場動態
    • 促進因素
    • 抑製器
    • 市場機會
    • 挑戰
  • 搬運工五力分析
    • 新進入者的威脅
    • 替代威脅
    • 客戶的議價能力
    • 供應商的談判能力
    • 行業競爭

第6章全球抗病毒藥物市場:按藥物分類

  • 簡介
  • HIV抗病毒藥
  • 肝炎抗病毒藥
  • 皰疹抗病毒藥
  • 流感抗病毒藥

第7章全球抗病毒藥物市場:按分佈

  • 簡介
  • 醫院藥房
  • 獨立藥房和藥房
  • 在線藥房

第8章美洲抗病毒治療市場

  • 簡介
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太抗病毒藥物市場

  • 簡介
  • 澳大利亞
  • 中國
  • 印度
  • 印度尼西亞
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第10章歐洲,中東/非洲抗病毒藥物市場

  • 簡介
  • 法國
  • 德國
  • 意大利
  • 荷蘭
  • 卡塔爾
  • 俄羅斯
  • 沙特阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合酋長國
  • 英國

第11章競爭情況

  • FPNV定位矩陣
    • 象限
    • 經營策略
    • 產品滿意度
  • 市場排名分析
  • 市場份額分析
  • 競爭性SWOT分析
  • 競爭情景
    • 併購
    • 協議,合作和夥伴關係
    • 推出和增強新產品
    • 投融資
    • 獎項,獎項,擴展

第12章企業可用性簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Atea Pharmaceuticals
  • Aurobindo Pharma Limited
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • COCRYSTAL PHARMA, INC.
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Services
  • Merck & Co.
  • Pfizer Inc.
  • Sanofi S.A.
  • Schering-Plough Corporation
  • Venatorx Pharmaceuticals, Inc.
  • Vienna BioCenter

第13章附錄

  • 討論指南
  • 許可證和價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MRR-037F3DB2592C

The Global Antiviral Therapeutics Market size was estimated at USD 58.29 Billion in 2020 and expected to reach USD 63.96 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 8.73% to reach USD 96.36 Billion by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Antiviral Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug, the Antiviral Therapeutics Market was studied across Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug, and Influenza Antiviral Drug.

Based on Therapy, the Antiviral Therapeutics Market was studied across DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors, and Reverse Transcriptase Inhibitors. The DNA Polymerase Inhibitors is further studied across Non-nucleosides, Purine Nucleoside Analogues, and Pyrimidine Nucleoside Analogues. The Reverse Transcriptase Inhibitors is further studied across Nonnucleoside RTIs, Nucleoside RTIs, and Nucleotide RTIs.

Based on Distribution, the Antiviral Therapeutics Market was studied across Hospital Pharmacy, Independent Pharmacy & Drug Store, and Online Pharmacy.

Based on Geography, the Antiviral Therapeutics Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Antiviral Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Antiviral Therapeutics Market, including Abbott Laboratories, AbbVie Inc., Atea Pharmaceuticals, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Cipla Inc., COCRYSTAL PHARMA, INC., Daiichi Sankyo Co. Ltd., Eli Lilly & Co., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Merck & Co., Pfizer Inc., Sanofi S.A., Schering-Plough Corporation, Venatorx Pharmaceuticals, Inc., and Vienna BioCenter.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Antiviral Therapeutics Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antiviral Therapeutics Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antiviral Therapeutics Market?
  • 4. What is the competitive strategic window for opportunities in the Global Antiviral Therapeutics Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Antiviral Therapeutics Market?
  • 6. What is the market share of the leading vendors in the Global Antiviral Therapeutics Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Antiviral Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug Outlook
  • 3.4. Therapy Outlook
  • 3.5. Distribution Outlook
  • 3.6. Geography Outlook
  • 3.7. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of viral diseases like HIV and Hepatitis
      • 5.1.1.2. Application of antiviral therapeutics in pediatric care and respiratory diseases
      • 5.1.1.3. Increasing initiatives to curb viral diseases by public and private companies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with antiviral drug treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in molecular biology promoting drug development
      • 5.1.3.2. Improved testing and analysis of viral infections
      • 5.1.3.3. Widespread immunisation programs supported by government
    • 5.1.4. Challenges
      • 5.1.4.1. Moving towards the development of new drug development formula
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Antiviral Therapeutics Market, by Drug

  • 6.1. Introduction
  • 6.2. Hepatitis Antiviral Drug
  • 6.3. Herpes Antiviral Drug
  • 6.4. HIV Antiviral Drug
  • 6.5. Influenza Antiviral Drug

7. Antiviral Therapeutics Market, by Therapy

  • 7.1. Introduction
  • 7.2. DNA Polymerase Inhibitors
    • 7.2.1. Non-nucleosides
    • 7.2.2. Purine Nucleoside Analogues
    • 7.2.3. Pyrimidine Nucleoside Analogues
  • 7.3. Neuraminidase Inhibitors
  • 7.4. Protease Inhibitors
  • 7.5. Reverse Transcriptase Inhibitors
    • 7.5.1. Nonnucleoside RTIs
    • 7.5.2. Nucleoside RTIs
    • 7.5.3. Nucleotide RTIs

8. Antiviral Therapeutics Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Independent Pharmacy & Drug Store
  • 8.4. Online Pharmacy

9. Americas Antiviral Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States
    • 9.6.1. California
    • 9.6.2. Florida
    • 9.6.3. Illinois
    • 9.6.4. New York
    • 9.6.5. Ohio
    • 9.6.6. Pennsylvania
    • 9.6.7. Texas

10. Asia-Pacific Antiviral Therapeutics Market

  • 10.1. Introduction
  • 10.2. China
  • 10.3. India
  • 10.4. Indonesia
  • 10.5. Japan
  • 10.6. Malaysia
  • 10.7. Philippines
  • 10.8. South Korea
  • 10.9. Thailand

11. Europe, Middle East & Africa Antiviral Therapeutics Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis, By Quadrant
  • 12.4. Market Share Analysis, By Company
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. Abbott Laboratories
  • 13.2. AbbVie Inc.
  • 13.3. Atea Pharmaceuticals
  • 13.4. Aurobindo Pharma Limited
  • 13.5. Bristol-Myers Squibb Company
  • 13.6. Cipla Inc.
  • 13.7. COCRYSTAL PHARMA, INC.
  • 13.8. Daiichi Sankyo Co. Ltd.
  • 13.9. Eli Lilly & Co.
  • 13.10. F. Hoffmann-La Roche AG
  • 13.11. Gilead Sciences Inc.
  • 13.12. GlaxoSmithKline PLC
  • 13.13. Johnson & Johnson Services
  • 13.14. Merck & Co.
  • 13.15. Pfizer Inc.
  • 13.16. Sanofi S.A.
  • 13.17. Schering-Plough Corporation
  • 13.18. Venatorx Pharmaceuticals, Inc.
  • 13.19. Vienna BioCenter

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
  • 14.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2020 VS 2026 (USD BILLION)
  • FIGURE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2020 (USD BILLION)
  • FIGURE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2020 (USD BILLION)
  • FIGURE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2020 (USD BILLION)
  • FIGURE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD BILLION)
  • FIGURE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: MARKET DYNAMICS
  • FIGURE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2020 VS 2026 (%)
  • FIGURE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2020 VS 2026 (USD BILLION)
  • FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2026
  • FIGURE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, 2018-2026 (USD BILLION)
  • FIGURE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 13. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, 2018-2026 (USD BILLION)
  • FIGURE 14. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 15. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, 2018-2026 (USD BILLION)
  • FIGURE 16. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 17. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, 2018-2026 (USD BILLION)
  • FIGURE 18. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 19. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2020 VS 2026 (%)
  • FIGURE 20. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2020 VS 2026 (USD BILLION)
  • FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2026
  • FIGURE 22. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2026 (USD BILLION)
  • FIGURE 23. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 24. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDES, 2018-2026 (USD BILLION)
  • FIGURE 25. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 26. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PURINE NUCLEOSIDE ANALOGUES, 2018-2026 (USD BILLION)
  • FIGURE 27. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PURINE NUCLEOSIDE ANALOGUES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 28. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PYRIMIDINE NUCLEOSIDE ANALOGUES, 2018-2026 (USD BILLION)
  • FIGURE 29. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PYRIMIDINE NUCLEOSIDE ANALOGUES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 30. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2026 (USD BILLION)
  • FIGURE 31. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 32. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2026 (USD BILLION)
  • FIGURE 33. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 34. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2026 (USD BILLION)
  • FIGURE 35. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 36. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NONNUCLEOSIDE RTIS, 2018-2026 (USD BILLION)
  • FIGURE 37. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NONNUCLEOSIDE RTIS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 38. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE RTIS, 2018-2026 (USD BILLION)
  • FIGURE 39. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE RTIS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 40. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE RTIS, 2018-2026 (USD BILLION)
  • FIGURE 41. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE RTIS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 42. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (%)
  • FIGURE 43. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (USD BILLION)
  • FIGURE 44. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2026
  • FIGURE 45. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2026 (USD BILLION)
  • FIGURE 46. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 47. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, 2018-2026 (USD BILLION)
  • FIGURE 48. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 49. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, 2018-2026 (USD BILLION)
  • FIGURE 50. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 51. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 52. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 53. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 54. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 55. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 56. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 57. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 58. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 59. CALIFORNIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 60. FLORIDA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 61. ILLINOIS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 62. NEW YORK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 63. OHIO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 64. PENNSYLVANIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 65. TEXAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 66. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 67. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 68. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 69. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 70. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 71. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 72. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 73. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 74. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 75. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 76. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 77. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 78. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 79. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 80. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 81. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 82. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 83. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 84. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 85. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 86. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 87. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 88. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 89. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 90. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 91. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 92. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 93. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 94. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTIVIRAL THERAPEUTICS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PURINE NUCLEOSIDE ANALOGUES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PYRIMIDINE NUCLEOSIDE ANALOGUES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 13. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 14. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 15. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 16. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NONNUCLEOSIDE RTIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 17. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE RTIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 18. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE RTIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 19. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 20. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 21. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 22. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 23. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 24. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 25. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 26. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 27. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 28. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 29. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 30. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 31. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 32. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 33. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 34. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 35. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 36. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 37. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 38. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 39. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 40. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 41. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 42. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 43. CALIFORNIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 44. CALIFORNIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 45. CALIFORNIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 46. FLORIDA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 47. FLORIDA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 48. FLORIDA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 49. ILLINOIS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 50. ILLINOIS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 51. ILLINOIS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 52. NEW YORK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 53. NEW YORK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 54. NEW YORK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 55. OHIO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 56. OHIO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 57. OHIO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 58. PENNSYLVANIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 59. PENNSYLVANIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 60. PENNSYLVANIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 61. TEXAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 62. TEXAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 63. TEXAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 64. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 65. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 66. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 67. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 68. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 69. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 70. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 71. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 72. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 73. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 74. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 75. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 76. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 77. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 78. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 79. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 80. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 81. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 82. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 83. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 84. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 85. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 86. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 87. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 88. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 89. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 90. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 91. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 96. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 97. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 98. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 99. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 100. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 101. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 102. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 103. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 104. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 105. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 106. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 107. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 108. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 109. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 110. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 111. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 112. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 113. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 114. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 115. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 116. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 117. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 118. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 119. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 120. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 121. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 122. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 123. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 124. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 125. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 126. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 127. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 128. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 129. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: SCORES
  • TABLE 130. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: BUSINESS STRATEGY
  • TABLE 131. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: PRODUCT SATISFACTION
  • TABLE 132. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: RANKING
  • TABLE 133. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 134. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 135. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: MERGER & ACQUISITION
  • TABLE 136. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 137. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 138. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: INVESTMENT & FUNDING
  • TABLE 139. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 140. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: LICENSE & PRICING
  • TABLE 141. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: CONTACT DETAILS